Patents by Inventor Tianyong Shi

Tianyong Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240425876
    Abstract: The present application relates to expression cassette combinations and uses thereof. The expression cassette combination comprises a first expression cassette and a second expression cassette, wherein the first expression cassette can express an N-terminal truncated version of an ABCA4 protein, the second expression cassette can express a C-terminal truncated version of an ABCA4 protein, and the N-terminal truncated version of the ABCA4 protein and the C-terminal truncated version of the ABCA4 protein can possess the biological functions of a complete ABCA4 protein without forming the complete ABCA4 protein therefrom.
    Type: Application
    Filed: February 16, 2023
    Publication date: December 26, 2024
    Inventors: Xiancheng Zhong, Shaohong Chen, Tianyong Shi
  • Patent number: 12065663
    Abstract: The present application relates to a vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2. The vector described herein has a good expression effect, high expression speed, and more stable expression intensity. The present application also provides cells, pharmaceutical compositions, and kits comprising the vector, and methods for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: August 20, 2024
    Assignee: CHIGENOVO CO., LTD
    Inventors: Liping Yang, Shaohong Chen, Ruixuan Jia, Fan Zhang, Saichao He, Tianyong Shi, Dandan Hao, Hongjie Pei, Luying Zeng
  • Publication number: 20240024433
    Abstract: The present application relates to the use of CYP4V2 and RdCVF in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy. The present application also relates to an isolated nucleic acid molecule comprising a polynucleotide encoding CYP4V2 and a polynucleotide encoding RdCVF. The present application also relates to an amino acid sequence encoded by the isolated nucleic acid molecule, a vector comprising the isolated nucleic acid molecule, and a cell comprising the nucleic acid or the vector as well as use thereof in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.
    Type: Application
    Filed: July 27, 2023
    Publication date: January 25, 2024
    Inventors: Liping Yang, Shaohong Chen, Ruixuan Jia, Fan Zhang, Qiaoli Zeng, Saichao He, Tianyong Shi, Dandan Hao, Shangwei Jiang, Hongjie Pei, Luying Zeng
  • Publication number: 20240018541
    Abstract: A vector includes a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2. The vector has a good expression effect, high expression speed, and more stable expression intensity. Cells, pharmaceutical compositions, and kits can include the vector. Methods for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy can include administering the vector to a subject.
    Type: Application
    Filed: July 13, 2022
    Publication date: January 18, 2024
    Inventors: Liping Yang, Shaohong Chen, Ruixuan Jia, Tianfu Zhang, Fan Zhang, Saichao He, Tianyong Shi, Dandan Hao, Hongjie Pei, Luying Zeng
  • Publication number: 20230399367
    Abstract: The present application relates to a fusion protein and use thereof. The fusion protein comprises RdCVF and a signal peptide, wherein the signal peptide is an amino acid sequence set forth in any one of SEQ ID NOs: 27-31 and 33. The present application also relates to an isolated nucleic acid molecule comprising a) a polynucleotide encoding RdCVF and b) a polynucleotide encoding a signal peptide. The present application also provides a vector, a cell, and a pharmaceutical composition containing the nucleic acid molecule, as well as medical use thereof. The fusion protein and/or isolated nucleic acid molecule described herein can effectively increase the secretion of RdCVF.
    Type: Application
    Filed: January 19, 2021
    Publication date: December 14, 2023
    Inventors: Shaohong Chen, Tianyong Shi, Dandan Hao, Saichao He, Linlin NIU
  • Publication number: 20230146121
    Abstract: The present application relates to the use of CYP4V2 and RdCVF in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy. The present application also relates to an isolated nucleic acid molecule comprising a polynucleotide encoding CYP4V2 and a polynucleotide encoding RdCVF. The present application also relates to an amino acid sequence encoded by the isolated nucleic acid molecule, a vector comprising the isolated nucleic acid molecule, and a cell comprising the nucleic acid or the vector as well as use thereof in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.
    Type: Application
    Filed: July 16, 2020
    Publication date: May 11, 2023
    Inventors: Liping Yang, Shaohong Chen, Ruixuan Jia, Tianfu Zhang, Fan Zhang, Qiaoli Zeng, Saichao He, Tianyong Shi, Dandan Hao, Shangwei Jiang, Hongjie PEI, Xudong Wang, Luying Zeng